我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

肠道微生态影响动脉粥样硬化发生发展的机制

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2017年第5期
页码:
614-616
栏目:
综述
出版日期:
2017-03-25

文章信息/Info

Title:
The mechanism of intestinal microecosystem effects on atherogenesis
作者:
张田田; 王长谦
（上海交通大学医学院附属第九人民医院心内科，上海 200011）
Author(s):
ZHANG Tian-tian;  WANG Chang-qian
（Department of Cardiology, Shanghai 9th People’s Hospital, Shanghai Jiaotong University Mecical School, Shanghai, 200011, China）
关键词:
肠道微生态; 动脉粥样硬化; 炎症; 氧化应激; 代谢性疾病
Keywords:
intestinal microecosystem;  atherosclerosis;  inflammation;  oxidative stress;  metabolic disease
分类号:
R543.5
DOI:
-
文献标识码:
A
摘要:
动脉粥样硬化（AS）不仅是一种炎症性疾病，而且属于一种代谢性疾病。肠道微生态的改变可对AS的发生发展产生双面影响。一方面，肠道菌群紊乱可以通过影响机体的胆碱代谢、氧化应激、炎症反应等机制直接促进AS产生发展，此外，可通过导致AS危险因素肥胖、高脂血症、糖尿病等的产生这些间接机制促AS的进展。另一方面，益生菌及益生元的增加则可有效地降低肠道微生物内毒素产生、增强肠道屏障、减轻机体质量、缓解炎症反应、改善胰岛素抵抗，进而在AS的进展方面发挥重要作用。因此，合理调控机体肠道微生态环境成为AS防治的新型重要手段。
Abstract:
Atherosclerosis is not only an inflammatory disease, but also a metabolic disease. The change of intestinal microecosystem can make double effects on atherogenesis. On the one hand, disordered intestinal microbes may accelerate atherogenesis through directly disturbing choline metabolism, oxidative stress, inflammation and so on. In addition, they could promote the development of atherosclerosis risk factors such as obesity, hyperlipidemia, and diabetes, which indirectly lead to atherogenesis. On the other hand, the increase of probiotics and prebiotics in the intestinal tract can effectively decrease the generation of endotoxin from intestinal microbes, enhance the barrier function, relieve body weights, remit inflammation, ameliorate the insulin resistance, thus to elimate the development of atherosclerosis. Therefore, reasonable adjustment of intestinal microecosystem will become an novel important prevention and therapy method for atherosclerosis.

参考文献/References

[1]Cénit MC,Matzaraki V,Tigchelaar EF,et al.Rapidly expanding knowledge on the role of the gut microbiome in health and disease[J].Biochim Biophys Acta,2014,1842(10):1981-1992.
[2]Xu MQ,Cao HL,Wang WQ,et al.Fecal microbiota transplantation broadening its application beyond intestinal disorders[J].World J Gastroenterol,2015,21(1):102-111.
[3]Husain K,Hernandez W,Ansari RA,et al.Inflammation, oxidative stress and renin angiotensin system in atherosclerosis[J].World J Biol Chem,2015,6(3):209-217.
[4]Franceschi F,Niccoli G,Ferrante G,et al.CagA antigen of Helicobacter pylori and coronary instability:insight from a clinico-pathological study and a meta-analysis of 4241 cases[J].Atherosclerosis,2009,202(2):535-542.
[5]Chistiakov DA,Bobryshev YV,Kozarov E,et al.Role of gut microbiota in the modulation of atherosclerosis-associated immune response[J].Front Microbiol,2015,6:671.
[6]Drosos I,Tavridou A,Kolios G.New aspects on the metabolic role of intestinal microbiota in the development of atherosclerosis[J].Metabolism,2015,64(4):476-481.
[7]Singh V,Yeoh BS,Vijay-Kumar M.Gut microbiome as a novel cardiovascular therapeutic target[J].Curr Opin Pharmacol,2016,27:8-12.
[8]Liu TX,Niu HT,Zhang SY.Intestinal Microbiota Metabolism and Atherosclerosis[J].Chin Med J(Engl),2015,128(20):2805-2811.
[9]Kivity S,Kopel E,Maor E,et al.Association of serum uric acid and cardiovascular disease in healthy adults[J].Am J Cardiol,2013,111(8):1146-1151.
[10]Kanbay M,Segal M,Afsar B,et al.The role of uric acid in the pathogenesis of human cardiovascular disease[J].Heart,2013,99(11):759-766.
[11]Kang DH,Ha SK.Uric Acid Puzzle:Dual Role as Anti-oxidantand Pro-oxidant[J].Electrolyte Blood Press,2014,12(1):1-6.
[12]Wang Y,Ames NP,Tun HM,et al.High Molecular Weight Barley β-Glucan Alters Gut Microbiota Toward Reduced Cardiovascular Disease Risk[J].Front Microbiol,2016,7:129.
[13]Boulangé CL,Neves AL,Chilloux J,et al.Impact of the gut microbiota on inflammation,obesity, and metabolic disease[J].Genome Med,2016,8(1):42.
[14]Sayin S,Wahlstrom A,Felin J,et al.Gut microbita regulated bile acid metabolism by reducing the levels of tauro-beta-muricholicacied,a naturally occurring FXR antagonist[J].Cell Metab,2013,17(2):225-235.
[15]Wang F,Zhang C,Zeng Q.Gut microbiota and immunopathogenesis of diabetes mellitus type 1 and 2[J].Front Biosci(Landmark Ed),2016,21:900-906.

备注/Memo

备注/Memo:
收稿日期：2016-04-29.基金资助：国家自然科学基金项目资助（81470546）；高等学校博士学科点专项科研基金项目资助（20130073110016）；上海市进一步加快中医药事业发展三年行动计划(2014年-2016年)项目资助（ZY3-CCCX-3-3002）
通讯作者： 王长谦，教授，主要从事动脉粥样硬化及冠心病防治研究 Email：wcqian@hotmail.com
作者简介：张田田，博士生 Email：zhangtiant0166@126.com
更新日期/Last Update: 2017-04-20